Five stages of evolving β-cell dysfunction during progression to diabetes

被引:813
作者
Weir, GC [1 ]
Bonner-Weir, S [1 ]
机构
[1] Joslin Diabet Ctr, Sect Islet Transplantat & Cell Biol, Boston, MA 02215 USA
关键词
D O I
10.2337/diabetes.53.suppl_3.S16
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This article proposes five stages in the progression of diabetes, each of which is characterized by different changes in beta-cell mass, phenotype, and function. Stage I is compensation: insulin secretion increases to maintain normoglycemia in the face of insulin resistance and/or decreasing -cell mass. This stage is characterized by maintenance of differentiated function with intact acute glucose-stimulated insulin secretion (GSIS). Stage 2 occurs when glucose levels start to rise, reaching similar to5.0-6.5 mmol/l; this is a stable state of beta-cell adaptation with loss of beta-cell mass and disruption of function as evidenced by diminished GSIS and beta-cell dedifferentiation. Stage 3 is a transient unstable period of early decompensation in which glucose levels rise relatively rapidly to the frank diabetes of stage 4, which is characterized as stable decompensation with more severe beta-cell dedifferentiation. Finally, stage 5 is characterized by severe decompensation representing a profound reduction in beta-cell mass with progression to ketosis. Movement across stages 1-4 can be in either direction. For example, individuals with treated type 2 diabetes can move from stage 4 to stage 1 or stage 2. For type 1 diabetes, as remission develops, progression from stage 4 to stage 2 is typically found. Delineation of these stages provides insight into the pathophysiology of both progression and remission of diabetes.
引用
收藏
页码:S16 / S21
页数:6
相关论文
共 46 条
[1]   NATURAL-HISTORY OF INTRAHEPATIC CANINE ISLET CELL AUTOGRAFTS [J].
ALEJANDRO, R ;
CUTFIELD, RG ;
SHIENVOLD, FL ;
POLONSKY, KS ;
NOEL, J ;
OLSON, L ;
DILLBERGER, J ;
MILLER, J ;
MINTZ, DH .
JOURNAL OF CLINICAL INVESTIGATION, 1986, 78 (05) :1339-1348
[2]  
American Diabetes Association, 2004, Diabetes Care, V27 Suppl 1, pS5, DOI 10.2337/diacare.27.2007.S5
[3]   ANALYSIS OF METABOLIC PROGRESSION TO TYPE-I DIABETES IN ICA+ RELATIVES OF PATIENTS WITH TYPE-I DIABETES [J].
BLEICH, D ;
JACKSON, RA ;
SOELDNER, JS ;
EISENBARTH, GS .
DIABETES CARE, 1990, 13 (02) :111-118
[4]   Life and death of the pancreatic β cells [J].
Bonner-Weir, S .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2000, 11 (09) :375-378
[5]   Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles [J].
Bruning, JC ;
Winnay, J ;
BonnerWeir, S ;
Taylor, SI ;
Accili, D ;
Kahn, CR .
CELL, 1997, 88 (04) :561-572
[6]   RELATIONSHIPS BETWEEN FASTING PLASMA GLUCOSE LEVELS AND INSULIN-SECRETION DURING INTRAVENOUS GLUCOSE-TOLERANCE TESTS [J].
BRUNZELL, JD ;
ROBERTSON, RP ;
LERNER, RL ;
HAZZARD, WR ;
ENSINCK, JW ;
BIERMAN, EL ;
PORTE, D .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1976, 42 (02) :222-229
[7]   β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes [J].
Butler, AE ;
Janson, J ;
Bonner-Weir, S ;
Ritzel, R ;
Rizza, RA ;
Butler, PC .
DIABETES, 2003, 52 (01) :102-110
[8]  
CERASI E, 1963, LANCET, V2, P1359
[9]   REGULATORY EFFECTS OF GLUCOSE ON THE CATALYTIC ACTIVITY AND CELLULAR CONTENT OF GLUCOKINASE IN THE PANCREATIC BETA-CELL - STUDY USING CULTURED RAT ISLETS [J].
CHEN, C ;
HOSOKAWA, H ;
BUMBALO, LM ;
LEAHY, JL .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (04) :1616-1620
[10]   DYNAMICS OF INSULIN SECRETION BY PERFUSED RAT PANCREAS [J].
CURRY, DL ;
BENNETT, LL ;
GRODSKY, GM .
ENDOCRINOLOGY, 1968, 83 (03) :572-&